Ascentage Pharma (AAPG) CMO details options, RSUs and share stakes
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
ASCENTAGE PHARMA GROUP INTERNATIONAL Chief Medical Officer Yifan Zhai filed an initial ownership report listing existing holdings, rather than new trades. The filing shows options and restricted share units over ordinary shares, vesting in four equal parts on each of 11/26/2026, 2027, 2028 and 2029, plus direct and indirect ordinary share positions held through a trust, spouse and HealthQuest Pharma Limited.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Zhai Yifan
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Restricted share units | -- | -- | -- |
| holding | Restricted share units | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Options — 143,463 shares (Indirect, See Footnote (2));
Options — 103,364 shares (Direct);
Restricted share units — 143,463 shares (Indirect, See Footnote (2));
Restricted share units — 103,364 shares (Direct);
Ordinary Shares — 1,097,994 shares (Indirect, See Footnote (2));
Ordinary Shares — 312,534 shares (Direct)
Footnotes (1)
- Shares held by Dajun Yang Dynasty Trust. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant. Securities held by ordinary shares held by HealthQuest Pharma Limited, an entity controlled by the Reporting Person. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.
FAQ
What does Ascentage Pharma (AAPG) Chief Medical Officer Yifan Zhai report in this Form 3?
The Form 3 reports Zhai’s existing ownership in Ascentage Pharma, not new trades. It lists options, restricted share units, and ordinary shares held directly and indirectly through a trust, spouse, and HealthQuest Pharma Limited, establishing her baseline insider position.
How many Ascentage Pharma (AAPG) options does Yifan Zhai hold and when do they vest?
The filing shows options linked to 143,463 ordinary shares indirectly and 103,364 directly at an exercise price of 8.1400. Footnotes state these stock options vest in four equal increments on each of 11/26/2026, 11/26/2027, 11/26/2028 and 11/26/2029.
When do Yifan Zhai’s Ascentage Pharma (AAPG) options expire and in what currency is the exercise price?
The options tied to ordinary shares expire on 11/26/2035. A footnote explains the exercise price is set in HKD, and the 8.1400 figure shown reflects conversion to USD based on the exchange rate on the grant date.
Does this Ascentage Pharma (AAPG) Form 3 show any insider buying or selling by Yifan Zhai?
The data classify all entries as holdings with unknown transaction codes, and the summary shows zero buys or sells. This indicates the Form 3 serves as an initial statement of beneficial ownership, not a record of new purchase or sale activity.